

> 定義 (Braunwald’s Heart Disease, 11th ed., 2019)


# HEART FAILURE

### 定義 (_Braunwald’s Heart Disease_, 11th ed., 2019)

• Failure of heart to pump blood forward at rate sufficient to meet metabolic demands of peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures

• Low output (↓ cardiac output) vs. high output (↑ stroke volume ± ↑ cardiac output)

• Left-sided (pulmonary edema) vs. right-sided (↑ JVP, hepatomegaly, peripheral edema)

• Backward (↑ filling pressures, congestion) vs. forward (impaired systemic perfusion)

• Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)

• Reduced (HFrEF, EF <40%), mid-range (HFmrEF, EF 40–49%), & preserved (HFpEF, EF >50%); combination of systolic and diastolic dysfxn may occur regardless of EF

### Figure 1-3 Approach to left-sided heart failure

![](https://i.imgur.com/07vs5kf.jpg)

### History

• Low output: fatigue, weakness, exercise intolerance, ∆ MS, anorexia

• Congestive: left-sided → dyspnea, orthopnea, paroxysmal nocturnal dyspnea

right-sided → peripheral edema, RUQ discomfort, bloating, satiety

### Functional classification (New York Heart Association class)

• Class I: no sx with ordinary activity; class II: sx with ordinary activity; class III: sx with minimal activity; class IV: sx at rest

### Physical exam (“2-minute” hemodynamic profile; _JAMA_ 1996;275:630 & 2002;287:628)

• **Congestion (“dry” vs. “wet”):** ↑ JVP (~80% of the time JVP >10 → PCWP >22)

⊕ hepatojugular reflux: ≥4 cm ↑ in JVP for ≥15 sec with abdominal pressure Se/Sp 73/87% for RA >8 and Se/Sp 55/83% for PCWP >15 (_AJC_ 1990;66:1002)

異常 Valsalva response: square wave (↑ SBP with strain), no overshoot (no ↑ BP after strain)

S3 (in 病人 with HF → ~40% ↑ risk of HF hosp. or pump failure death; _NEJM_ 2001;345:574)

rales, dullness at base 2° pleural effus. (_often absent_ in chronic HF due to lymphatic compensation) ± hepatomegaly, ascites and jaundice, peripheral edema

• **Perfusion (“warm” _vs._ “cold”)**

narrow pulse pressure (<25% of SBP) → CI <2.2 (91% Se, 83% Sp; _JAMA_ 1989;261:884);

soft S1 (↓ dP/dt), pulsus alternans, cool & pale extremities, ↓ UOP, muscle atrophy

• ± Other: Cheyne-Stokes resp., 異常 PMI (diffuse, sustained or lifting depending on cause of HF), S4 (diast. dysfxn), murmur (valvular dis., ↑ MV annulus, displaced papillary muscles)

### Evaluation for the presence of heart failure

• CXR (see Radiology insert): pulm edema, pleural effusions ± cardiomegaly, cephalization, Kerley B-lines; lung U/S better than CXR (PPV & NPV 92% vs. 77%; _Chest_ 2015;148:202)

• BNP/NT-proBNP can help exclude HF; levels ↑ with age, renal dysfxn, AF; ↓ with obesity Se ≥95%, Sp: ~50%, PPV ~65%, NPV ≥ 94% for HF in 病人 表現為 SOB (_BMJ_ 2015;350:h910)

• Evidence of ↓ organ perfusion: ↑ Cr, ↓ Na, 異常 LFTs

• Echo (see inserts): ↓ EF & ↑ chamber size → systolic dysfxn; hypertrophy, 異常 MV inflow, 異常 tissue Doppler → ? diastolic dysfxn; 異常 valves or pericardium; ↑ estimated RVSP

• PA catheterization: ↑ PCWP, ↓ CO, and ↑ SVR (in low-output failure)

### Evaluation for the potential causes of heart failure

• **ECG:** evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCMP)

• **TTE:** LV & RV size & fxn, valve 異常 (cause or consequence?), infiltrative or pericardial dis.

• **Cardiac MRI:** distinguishes ischemic vs. nonischemic and can help determine etiol. of latter

• **Coronary angio** (or noninvasive imaging, eg, CT angio); if no CAD, workup for NICM

### Precipitants of acute heart failure

• **Dietary indiscretion or medical nonadherence** (~40% of cases)

• **Myocardial ischemia or infarction** (~10–15% of cases); myocarditis

• **Renal failure** (acute, progression of CKD, or insufficient dialysis) → ↑ preload

• **Hypertensive crisis (incl. from RAS)**, **worsening AS** → ↑ left-sided afterload

• **Drugs** (βB, CCB, NSAIDs, TZDs), **chemo** (anthracyclines, trastuzumab), or **toxins** (EtOH)

• **Arrhythmias; acute valvular dysfxn** (eg, endocarditis), espec mitral or aortic regurgitation

• COPD/PE → ↑ right-sided afterload; extreme stress; anemia; systemic infxn; thyroid dis.

![](https://i.imgur.com/Kbwubyz.jpg)

### Rx of acute decompens. HF (_NEJM_ 2017;377:1964)

• Assess degree of congestion & adequacy of perfusion

• For **congestion: “LMNOP”**

### Lasix IV; total daily dose 2.5× usual daily PO dose → ↑ UOP, but transient ↑ in Cr vs. 1× usual dose; ∅ clear diff between contin. gtt vs. q12h (_NEJM_ 2011;364:797)

### Morphine (↓ sx, venodilator, ↓ afterload)

### Nitrates (venodilator)

### Oxygen ± noninvasive vent (↓ sx, ↑ PaO2; no ∆ mortality; see “Mechanical Ventilation”)

### Position (sitting up & legs dangling over side of bed → ↓ preload)

• For **low perfusion**, see below

• Adjustment of oral meds

ACEI/ARB: hold if HoTN, consider ∆ to hydralazine & nitrates if renal decompensation

βB: reduce dose by at least 1/2 if mod HF, d/c if severe HF and/or need inotropes

### 治療 of acute advanced heart failure (_Circ_ 2009;119:e391)

• Consider PAC if not resp to Rx, unsure re: vol status, HoTN, ↑ Cr, need inotropes

• Tailored Rx with PAC (qv); goals of MAP >60, CI >2.2 (MVO2 >60%), SVR <800, PCWP <18

• **IV vasodilators:** NTG, nitroprusside (risk of coronary steal if CAD)

• **Inotropes** (properties in addition to ↑ inotropy listed below)

dobutamine: vasodilation at doses ≤5 µg/kg/min; mild ↓ PVR; desensitization over time

dopamine: splanchnic vasodil. → ↑ GFR & natriuresis; vasoconstrictor at ≥5 µg/kg/min

milrinone: prominent systemic & pulmonary vasodilation; ↓ dose by 50% in renal failure

• **Mechanical circulatory support** (also see “Tailored Therapy;” _JACC_ 2015;65:e7 & 2542)

_Temporary:_ bridge to recovery, transplant, or durable MCS; periprocedural support

Intra-aortic balloon pump (IABP): inflates in diastole & deflates in systole to ↓ impedance to LV ejection, ↓ myocardial O2 demand & ↑ coronary perfusion. +0.5 L/min CO

Axial flow pumps (eg, Impella): Archimedes screw principle in LV; +2.5–5 L/min

Extracorporeal centrifugal pumps: TandemHeart (+5 L/min, percutaneous) & CentriMag (10 L/min, surgical)

Extracorporeal membrane oxygenation (ECMO): 6 L/min (_JACC HF_ 2018;6:503)

_Durable:_ surgically placed LVAD ± RVAD as bridge to sufficient recovery (in 5–50% of niCMP; _JACC_ 2017;69:1924), to transplant or as destination Rx (>50% ↓ 1-y mort. vs. med Rx; _NEJM_ 2001;345:1435 & 2009;361:2241). Fully magnetically levitated centrifugal flow pump (HeartMate 3) ↓ stroke or re-op vs. axial flow HeartMate II (_NEJM_ 2019;380:1618); HeartWare LVAD another centrifugal option (_NEJM_ 2017;376:451).

• Cardiac transplantation: ~2500/yr in U.S. 10% mort. in 1st y, median survival ~10 y

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Recommended Chronic Therapy by HF Stage</b> (<span><i>Circ</i> 2009;119:e391</span>)</p></td></tr><tr><td colspan="2"><p><b>Stage</b> (not NYHA Class)</p></td><td><p><b>Therapy</b></p></td></tr><tr><td><p><b>A</b></p></td><td><p>At risk for HF (eg, HTN, FHx CMP); but asx &amp; without struct. heart dis.</p></td><td><p>Rx HTN, lipids, DM.</p><p>Stop smoking, EtOH. ↑ exercise.</p><p>ACEI/ARB if HTN/DM/CAD/PAD</p></td></tr><tr><td><p><b>B</b></p></td><td><p>⊕ Struct. heart dis.</p><p>(eg, CMP, LVH), but asx</p></td><td><p>As per stage A + ACEI/ARB &amp; βB if MI/CAD or ↓ EF. ? ICD.</p></td></tr><tr><td><p><b>C</b></p></td><td><p>⊕ Struct. heart dis.</p><p>⊕ Any h/o Sx of HF</p></td><td><p>As per stage A + diuretics, ↓ Na. If ↓ EF: ACEI, ARB or ARNI; βB; aldo antag; ICD; ? CRT; nitrate/hydral; dig.</p></td></tr><tr><td><p><b>D</b></p></td><td><p>Refractory HF requiring specialized interventions</p></td><td><p>All measures for stages A–C. Consider IV inotropes, VAD, transplant, end-of-life care (4-y mortality &gt;50%)</p></td></tr></tbody></table>

• Utility of BNP-guided Rx (inPt and outPt) remains debated (_Eur Heart J_ 2014;35:16)

• Implantable PA pressure sensor in NYHA III → ~33% ↓ risk of hosp (_Lancet_ 2016;387:453)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><a id="page_1-16"></a><b>治療 of Chronic HF with Reduced EF</b> (<span><i>JACC</i> 2017;70:776</span>)</p></td></tr><tr><td><p>Diet, exercise</p></td><td><p>Na &lt;2 g/d, fluid restriction, exercise training in ambulatory 病人</p></td></tr><tr><td><p>BP</p></td><td><p>Goal &lt;130/80 (<span><i>JACC</i> 2018;71:127</span>)</p></td></tr><tr><td><p><b>ACEI</b></p></td><td><p>↓ mortality: 40% in NYHA IV, 16% in NYHA II/III, 20–30% in asx but ↓ EF (<span><i>NEJM</i> 1992;327:685; <i>Lancet</i> 2000;355:1575</span>)</p><p>High-dose more effic. than low. Watch for ↑ Cr, ↑ K (ameliorate by low-K diet, diuretics, K binders), cough, angioedema.</p></td></tr><tr><td><p><b>ATII receptor blockers (ARBs)</b></p></td><td><p><i>Consider as alternative if cannot tolerate ACEI (eg, b/c cough)</i></p><p>Noninferior to ACEI (<span><i>Lancet</i> 2000;355:1582 &amp; 2003;362:772</span>)</p><p>As with ACEI, higher doses more efficacious (<span><i>Lancet</i> 2009;379:1840</span>)</p><p>Adding to ACEI → ↑ risk of ↑ K and ↑ Cr (<i>BMJ</i> 2013;346:f360)</p></td></tr><tr><td><p><b>ARNI</b> (ARB + neprilysin inhib)</p><p><i>(do not use with ACEI, allow 36-h washout)</i></p></td><td><p><i>Preferred RAAS inhib in NYHA II-IV</i>. Neutral endopeptidase (NEP, aka neprilysin) degrades natriuretic peptides, bradykinin &amp; angiotensins. Valsartan + sacubitril (NEPi) ↓ CV mort &amp; HF hosp c/w ACEi; ↑ HoTN, AKI (<i>NEJM</i> 2014;371:993 &amp; 2019;380:539). Contraindicated if h/o angioedema.</p></td></tr><tr><td><p>Hydralazine + nitrates</p></td><td><p><i>Consider if cannot tolerate ACEI/ARB or in blacks with class III/IV</i></p><p>25% ↓ mort. (<span><i>NEJM</i> 1986;314:1547</span>); infer. to ACEI (<i>NEJM</i> 1991;325:303)</p><p>40% ↓ mort. in blacks on standard Rx (A-HEFT, <i>NEJM</i> 2004;351:2049)</p></td></tr><tr><td><p>β<b>-blocker</b></p><p>(data for carvedilol, metoprolol, bisoprolol)</p></td><td><p><i>EF will transiently</i> ↓, <i>then</i> ↑<i>. Contraindic. in decompensated HF.</i></p><p>35% ↓ mort. &amp; 40% ↓ rehosp. in NYHA II–IV (<span><i>JAMA</i> 2002;287:883</span>)</p><p>Carvedilol superior to low-dose metop in 1 trial (<span><i>Lancet</i> 2003;362:7</span>), but meta-analysis suggests no diff between βB (<span><i>BMJ</i> 2013;346:f55</span>).</p></td></tr><tr><td><p><b>Aldosterone antagonists</b></p></td><td><p><i>Consider if adeq. renal fxn and without hyperkalemia; watch for</i> ↑ <i>K</i></p><p>25–30% ↓ mort. in NYHA II–IV &amp; EF ≤35% (<span><i>NEJM</i> 2011;364:11</span>)</p><p>15% ↓ mort. in HF post-MI, EF ≤40% (EPHESUS, <span><i>NEJM</i> 2003;348:1309</span>)</p></td></tr><tr><td><p><b>Cardiac resynch therapy (CRT, qv)</b></p></td><td><p><i>Consider if EF</i> ≤<i>35%, LBBB (QRS</i> ≥1<i>30 ms) and symptomatic HF</i></p><p>36% ↓ mort. &amp; ↑ EF in NYHA III–IV (CARE-HF, <span><i>NEJM</i> 2005;352:1539</span>)</p><p>41% ↓ mort. if EF ≤30%, LBBB and NYHA I/II (<span><i>NEJM</i> 2014;370:1694</span>)</p></td></tr><tr><td><p><b>ICD</b> (see “Cardiac Rhythm Mgmt Devices”)</p></td><td><p><i>For</i> 1° <i>prevention if EF</i> ≤<i>30–35</i>% or 2° <i>prevention; not if NYHA IV</i></p><p>↓ mort. in ischemic CMP but perhaps only SCD in modern era in niCMP (<span><i>NEJM</i> 2005;352:225 &amp; 2016;375:1221</span>)</p></td></tr><tr><td><p>Diuretics</p></td><td><p>Loop ± thiazides diuretics (sx relief; no mortality benefit)</p></td></tr><tr><td><p>Digoxin</p></td><td><p>23% ↓ HF hosp., no ∆ mort (<i>NEJM</i> 1997;336:525); ? ↑ mort with ↑ levels (<span><i>NEJM</i> 2002;347:1403</span>); optimal 0.5–0.8 ng/mL (<span><i>JAMA</i> 2003;289:871</span>)</p></td></tr><tr><td><p>Ivabradine (I<i><sub>f</sub></i> blocker without ⊖ ino)</p></td><td><p><i>Consider if EF</i> ≤<i>35%, NYHA II or III, HR</i> ≥<i>70, NSR on max</i> β<i>B.</i> 18% ↓ CV mort or HF hosp (<span><i>Lancet</i> 2010;376:875</span>)</p></td></tr><tr><td><p>Iron supplementation</p></td><td><p><i>? IV (not PO) if NYHA II/III, EF</i> ≤<i>40%, Fe-defic</i> (ferritin &lt;100 or 100–300 &amp; TSAT &lt;20%). ↑ 生活品質 independent of Hct (<span><i>NEJM</i> 2009;361:2436</span>).</p></td></tr><tr><td><p>Anticoagulation</p></td><td><p><i>If AF, VTE, LV thrombus</i>, ± <i>if large akinetic LV segments.</i> In SR with rEF, ↓ isch stroke, but ↑ bleed (<span><i>NEJM</i> 2012;366:1859 &amp; 2018;379:1332</span>).</p></td></tr><tr><td><p>Heart rhythm</p></td><td><p>If AF &amp; NYHA II-IV with EF &lt;35%, catheter ablation ↓ D/HF hosp vs. med Rx (rate or rhythm; <span><i>NEJM</i> 2018;378:417</span>)</p></td></tr><tr><td><p>Other</p></td><td><p>SGLT2i ↓ death/HF hosp in DM (<span><i>Lancet</i> 2019;393:31</span>)</p></td></tr><tr><td><p>Meds to avoid</p></td><td><p>NSAIDs, nondihydropyridine CCB, TZDs</p></td></tr></tbody></table>

(_Circ_ 2013;128:e240 & 2016;134:e282; _EHJ_ 2016;37:2129)

### Heart failure with preserved EF (HFpEF; “Diastolic HF”) (_NEJM_ 2016;375:1868)

• 流行病學: ~1/2 of 病人 with HF have normal or only min. impaired systolic fxn (EF ≥40%); risk factors for HFpEF incl ↑ age, ♀, DM, AF. Mortality ≈ to those with systolic dysfxn.

• 原因 (impaired relaxation and/or ↑ passive stiffness): ischemia, prior MI, LVH, HCMP, infiltrative CMP, RCMP, aging, hypothyroidism

• Precipitants of pulmonary edema: _volume overload_ (poor compliance of LV → sensitive to even modest ↑ in volume); _ischemia_ (↓ relaxation); _tachycardia_ (↓ filling time in diastole), _AF_ (loss of atrial boost to LV filling); _HTN_ (↑ afterload → ↓ stroke volume)

• Dx with 臨床signs and symptoms of HF with preserved systolic fxn. Dx supported by evidence of diast dysfxn:

(1) echo: 異常 MV inflow (E/A reversal and ∆s in E wave deceleration time) & ↓ myocardial relax. (↑ isovol relax. time & ↓ early diastole tissue Doppler vel)

(2) exercise-induced ↑ PCWP (± ↓ response chronotropic & vasodilator reserve)

• 治療: diuresis for vol overload, BP control, prevention of tachycardia and ischemia;

no benefit to: ACEI/ARB (_NEJM_ 2008;359:2456) or PDE5 inhib (_JAMA_ 2013;309:1268);

spironolactone ? ↓ CV death & HF hosp (at least in Americas) (_NEJM_ 2014;370:1383);

ARNi (_JACC Heart Fail_ 2017;5:471) under study; transcatheter interatrial shunt reduces

PCWP during exercise, ? whether improves sx/outcomes (_Circ_ 2017;137:364)
